Adial Historical Balance Sheet

ADIL Stock

USD 0.70 0.01 1.41%

Trend analysis of Adial Pharmaceuticals balance sheet accounts such as Other Current Liab of 765.3 K, Total Current Liabilities of 1.1 M or Total Stockholder Equity of 3.3 M provides information on Adial Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Adial Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Adial Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Adial Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Adial Pharmaceuticals is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.

About Adial Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Adial Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Adial Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Adial Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Adial currently owns. An asset can also be divided into two categories, current and non-current.

Adial Pharmaceuticals Balance Sheet Chart

At this time, Adial Pharmaceuticals' Capital Surpluse is quite stable compared to the past year. Other Current Assets is expected to rise to about 367.4 K this year, although the value of Total Stockholder Equity will most likely fall to about 3.3 M.

Total Assets Other Current Liab Total Current Liabilities Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of Adial Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Adial Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Adial Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Adial Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Adial Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Adial Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Adial Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Adial Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.At this time, Adial Pharmaceuticals' Capital Surpluse is quite stable compared to the past year. Other Current Assets is expected to rise to about 367.4 K this year, although the value of Total Stockholder Equity will most likely fall to about 3.3 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	1.4M	525.7K	725.7K	765.3K
Total Assets	5.7M	4.7M	5.0M	4.5M

Other Current Liab Total Assets

Adial Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Capital Surpluse	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Short Long Term Debt Total	Net Receivables	Short Long Term Debt	Other Stockholder Equity
Total Assets		0.77	0.71	0.94	0.91	-0.99	-0.67	0.61	0.99	0.61	0.46	0.83	0.99	-0.84	0.28	0.85	0.83	0.68	0.99	-0.14	0.48	-0.84	-0.23	-0.22	0.82	0.79
Other Current Liab	0.77		0.94	0.53	0.46	-0.72	-0.65	0.53	0.74	0.69	0.38	0.61	0.74	-0.62	0.2	0.73	0.71	0.96	0.72	-0.09	0.84	-0.62	-0.17	-0.16	0.61	0.71
Total Current Liabilities	0.71	0.94		0.44	0.38	-0.64	-0.59	0.7	0.68	0.63	0.36	0.7	0.68	-0.71	0.2	0.66	0.71	0.98	0.67	0.21	0.77	-0.71	0.13	-0.16	0.69	0.66
Total Stockholder Equity	0.94	0.53	0.44		0.99	-0.95	-0.58	0.5	0.94	0.49	0.44	0.76	0.94	-0.76	0.28	0.79	0.74	0.39	0.95	-0.23	0.2	-0.76	-0.32	-0.22	0.76	0.7
Net Tangible Assets	0.91	0.46	0.38	0.99		-0.94	-0.46	0.51	0.93	0.34	0.31	0.71	0.93	-0.71	0.22	0.71	0.71	0.33	0.94	-0.25	0.16	-0.71	-0.29	-0.17	0.71	0.59
Net Debt	-0.99	-0.72	-0.64	-0.95	-0.94		0.6	-0.58	-1.0	-0.5	-0.4	-0.78	-1.0	0.78	-0.29	-0.83	-0.78	-0.61	-0.99	0.2	-0.41	0.78	0.26	0.25	-0.76	-0.71
Retained Earnings	-0.67	-0.65	-0.59	-0.58	-0.46	0.6		-0.36	-0.58	-0.88	-0.92	-0.69	-0.58	0.64	-0.72	-0.92	-0.65	-0.55	-0.57	0.0	-0.37	0.64	0.32	0.64	-0.6	-0.95
Accounts Payable	0.61	0.53	0.7	0.5	0.51	-0.58	-0.36		0.61	0.3	0.26	0.77	0.61	-0.78	0.2	0.54	0.75	0.58	0.62	0.29	0.22	-0.78	0.3	-0.18	0.76	0.47
Cash	0.99	0.74	0.68	0.94	0.93	-1.0	-0.58	0.61		0.51	0.37	0.8	1.0	-0.81	0.25	0.8	0.79	0.65	1.0	-0.15	0.45	-0.81	-0.2	-0.2	0.79	0.71
Non Current Assets Total	0.61	0.69	0.63	0.49	0.34	-0.5	-0.88	0.3	0.51		0.77	0.61	0.51	-0.6	0.37	0.78	0.6	0.61	0.49	0.0	0.49	-0.6	-0.26	-0.25	0.61	0.92
Non Currrent Assets Other	0.46	0.38	0.36	0.44	0.31	-0.4	-0.92	0.26	0.37	0.77		0.61	0.37	-0.54	0.84	0.79	0.4	0.29	0.36	0.13	0.02	-0.54	-0.2	-0.77	0.48	0.82
Other Assets	0.83	0.61	0.7	0.76	0.71	-0.78	-0.69	0.77	0.8	0.61	0.61		0.8	-0.99	0.46	0.75	0.73	0.61	0.8	0.36	0.29	-0.99	0.22	-0.41	0.96	0.78
Cash And Short Term Investments	0.99	0.74	0.68	0.94	0.93	-1.0	-0.58	0.61	1.0	0.51	0.37	0.8		-0.81	0.25	0.8	0.79	0.65	1.0	-0.15	0.45	-0.81	-0.2	-0.2	0.79	0.71
Common Stock Total Equity	-0.84	-0.62	-0.71	-0.76	-0.71	0.78	0.64	-0.78	-0.81	-0.6	-0.54	-0.99	-0.81		-0.37	-0.72	-0.74	-0.63	-0.81	-0.35	-0.32	1.0	-0.24	0.31	-0.97	-0.75
Common Stock Shares Outstanding	0.28	0.2	0.2	0.28	0.22	-0.29	-0.72	0.2	0.25	0.37	0.84	0.46	0.25	-0.37		0.6	0.18	0.14	0.24	0.17	-0.12	-0.37	-0.12	-0.95	0.3	0.57
Capital Surpluse	0.85	0.73	0.66	0.79	0.71	-0.83	-0.92	0.54	0.8	0.78	0.79	0.75	0.8	-0.72	0.6		0.82	0.62	0.8	-0.16	0.38	-0.72	-0.4	-0.54	0.67	0.92
Other Current Assets	0.83	0.71	0.71	0.74	0.71	-0.78	-0.65	0.75	0.79	0.6	0.4	0.73	0.79	-0.74	0.18	0.82		0.65	0.8	-0.13	0.53	-0.74	-0.24	-0.15	0.72	0.74
Total Liab	0.68	0.96	0.98	0.39	0.33	-0.61	-0.55	0.58	0.65	0.61	0.29	0.61	0.65	-0.63	0.14	0.62	0.65		0.63	0.14	0.85	-0.63	0.07	-0.12	0.6	0.61
Total Current Assets	0.99	0.72	0.67	0.95	0.94	-0.99	-0.57	0.62	1.0	0.49	0.36	0.8	1.0	-0.81	0.24	0.8	0.8	0.63		-0.15	0.43	-0.81	-0.2	-0.2	0.8	0.7
Short Term Debt	-0.14	-0.09	0.21	-0.23	-0.25	0.2	0.0	0.29	-0.15	0.0	0.13	0.36	-0.15	-0.35	0.17	-0.16	-0.13	0.14	-0.15		-0.08	-0.35	0.88	-0.2	0.32	-0.01
Intangible Assets	0.48	0.84	0.77	0.2	0.16	-0.41	-0.37	0.22	0.45	0.49	0.02	0.29	0.45	-0.32	-0.12	0.38	0.53	0.85	0.43	-0.08		-0.32	-0.11	0.14	0.33	0.43
Common Stock	-0.84	-0.62	-0.71	-0.76	-0.71	0.78	0.64	-0.78	-0.81	-0.6	-0.54	-0.99	-0.81	1.0	-0.37	-0.72	-0.74	-0.63	-0.81	-0.35	-0.32		-0.24	0.31	-0.97	-0.75
Short Long Term Debt Total	-0.23	-0.17	0.13	-0.32	-0.29	0.26	0.32	0.3	-0.2	-0.26	-0.2	0.22	-0.2	-0.24	-0.12	-0.4	-0.24	0.07	-0.2	0.88	-0.11	-0.24		0.06	0.21	-0.28
Net Receivables	-0.22	-0.16	-0.16	-0.22	-0.17	0.25	0.64	-0.18	-0.2	-0.25	-0.77	-0.41	-0.2	0.31	-0.95	-0.54	-0.15	-0.12	-0.2	-0.2	0.14	0.31	0.06		-0.18	-0.43
Short Long Term Debt	0.82	0.61	0.69	0.76	0.71	-0.76	-0.6	0.76	0.79	0.61	0.48	0.96	0.79	-0.97	0.3	0.67	0.72	0.6	0.8	0.32	0.33	-0.97	0.21	-0.18		0.77
Other Stockholder Equity	0.79	0.71	0.66	0.7	0.59	-0.71	-0.95	0.47	0.71	0.92	0.82	0.78	0.71	-0.75	0.57	0.92	0.74	0.61	0.7	-0.01	0.43	-0.75	-0.28	-0.43	0.77

Click cells to compare fundamentals

Adial Pharmaceuticals Account Relationship Matchups

Adial Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	5.5M	7.5M	5.7M	4.7M	5.0M	4.5M
Other Current Liab	856.6K	2.4M	1.4M	525.7K	725.7K	765.3K
Total Current Liabilities	1.5M	2.7M	1.8M	653.1K	975.9K	1.1M
Total Stockholder Equity	4.0M	3.5M	3.3M	4.1M	4.1M	3.3M
Net Tangible Assets	4.4M	7.1M	4.0M	2.8M	3.2M	2.7M
Net Debt	(4.4M)	(5.8M)	(3.8M)	(2.8M)	(3.8M)	(3.9M)
Retained Earnings	(31.5M)	(50.9M)	(63.7M)	(68.8M)	(82.0M)	(77.9M)
Accounts Payable	648.7K	286.2K	276.4K	127.4K	250.1K	268.0K
Cash	4.4M	6.1M	4.0M	2.8M	3.8M	3.5M
Non Current Assets Total	355.6K	1.0M	952.9K	1.5M	985.2K	537.5K
Non Currrent Assets Other	0.0	350K	455K	1.5M	1.8M	1.9M
Cash And Short Term Investments	4.4M	6.1M	4.0M	2.8M	3.8M	3.5M
Common Stock Shares Outstanding	498.5K	743.5K	1.1M	1.4M	18.6M	19.5M
Liabilities And Stockholders Equity	5.5M	7.5M	5.7M	4.7M	5.0M	4.5M
Other Current Assets	734.7K	399.4K	778.1K	371.6K	308.2K	367.4K
Total Liab	1.5M	4.0M	2.5M	653.1K	975.9K	1.3M
Total Current Assets	5.1M	6.5M	4.8M	3.2M	4.1M	4.0M
Intangible Assets	5.6K	460.0K	459.5K	3.9K	3.3K	3.2K
Common Stock	14.4K	20.9K	26.7K	1.7K	6.5K	6.1K
Other Stockholder Equity	35.5M	54.4M	66.9M	72.9M	86.1M	49.4M
Net Invested Capital	4.0M	3.5M	3.3M	4.1M	4.7M	4.1M
Net Working Capital	3.6M	3.7M	3.0M	3.1M	3.5M	3.8M
Capital Stock	14.4K	20.9K	26.7K	6.5K	7.4K	7.1K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Adial Pharmaceuticals is a strong investment it is important to analyze Adial Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adial Pharmaceuticals' future performance. For an informed investment choice regarding Adial Stock, refer to the following important reports:

How To Invest In Adial

Details

Is Adial Stock a good investment?

Details

What is Adial Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.

You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.72)

Return On Assets

(1.06)

Return On Equity

(3.24)

The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Adial Historical Balance Sheet

About Adial Balance Sheet Analysis

Adial Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Adial Pharmaceuticals balance sheet Correlations

Adial Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Adial Pharmaceuticals balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Cash	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Common Stock	- 0.99	Other Assets
Common Stock Total Equity	- 0.99	Other Assets
Total Current Assets	- 0.99	Net Debt
Net Debt	- 0.99	Total Assets